NCT07000318View on ClinicalTrials.gov

CS-206 in Patients With Sickle Cell Disease

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Sickle Cell Disease
Interventions
GENETIC

CS-206

Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique

Trial Locations (1)

201102

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Children's Hospital of Fudan University

OTHER